



XEMPERIA®

bio-inspired diagnostics

Breast cancer is a major threat for women worldwide

One woman out of 8 will develop breast cancer during her life time.

Early detection saves lives.

But cancer screening by mammography is highly ineffective and expensive.

We have a solution:

Imagine a simple and accurate breast cancer detection test accessible to all women!

An innovative blood test for breast cancer detection.

This is our goal!




The need to improve breast cancer screening

Early detection by mammography saves lives, but it has major limitations:

- It's highly ineffective
(1 out of 100 mammographies is positive,
1 out of 5 positive is real breast cancer)
- Expensive to the health system
- No screening before 50 years
(25% breast cancers appear before this age)
- 40% of cancers are missed

XEMPERIA's test will be the first screening step



A breast cancer detection blood test based on cancer biology

XEMPERIA's test will be a game changer in breast cancer early diagnostic:


- Accessible to all woman at their doctor's office
- Extremely reliable
- Quick and easy (non-invasive)

Who we are

XEMPERIA is a spin-off company of UNIFR built on over 25 years of experience in experimental and translational breast cancer research and biomarker discovery.

Our **vision** is to advance innovation and become leaders in the field of blood tests for cancer detection and monitoring.

Our **mission** is to reduce cancer mortality and improving patients' quality of life by identifying and addressing cancer at its earliest and most treatable stage.



The test detects a molecular signature in circulating immune cells using PCR and a proprietary algorithm. It gives a score for the presence or absence of breast cancer.

contact@xemperia.com
www.xemperia.com

